Richard P Slaughter Associates Inc Acquires 1,555 Shares of Pfizer Inc. (NYSE:PFE)

Richard P Slaughter Associates Inc grew its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 3.7% in the fourth quarter, HoldingsChannel reports. The fund owned 43,411 shares of the biopharmaceutical company’s stock after purchasing an additional 1,555 shares during the quarter. Richard P Slaughter Associates Inc’s holdings in Pfizer were worth $2,224,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the business. CWA Asset Management Group LLC boosted its holdings in Pfizer by 4.3% in the 4th quarter. CWA Asset Management Group LLC now owns 341,153 shares of the biopharmaceutical company’s stock worth $17,481,000 after buying an additional 14,105 shares during the period. Radnor Capital Management LLC boosted its holdings in Pfizer by 3.8% in the 4th quarter. Radnor Capital Management LLC now owns 49,917 shares of the biopharmaceutical company’s stock worth $2,649,000 after buying an additional 1,817 shares during the period. Align Wealth Management LLC bought a new position in Pfizer in the 4th quarter worth $45,000. Parkside Advisors LLC bought a new position in Pfizer in the 4th quarter worth $377,000. Finally, Brookstone Capital Management boosted its holdings in Pfizer by 2.8% in the 4th quarter. Brookstone Capital Management now owns 104,420 shares of the biopharmaceutical company’s stock worth $5,317,000 after buying an additional 2,890 shares during the period. Institutional investors own 67.62% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on PFE shares. Wells Fargo & Company dropped their price objective on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating for the company in a report on Friday. BMO Capital Markets dropped their price objective on shares of Pfizer from $55.00 to $53.00 and set an “outperform” rating for the company in a report on Wednesday, February 1st. Berenberg Bank set a $40.00 price objective on shares of Pfizer in a report on Tuesday, February 7th. Jefferies Financial Group started coverage on shares of Pfizer in a report on Monday, March 6th. They set a “hold” rating and a $43.00 price objective for the company. Finally, SVB Leerink dropped their price objective on shares of Pfizer from $49.00 to $48.00 and set a “market perform” rating for the company in a report on Wednesday, February 1st. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $50.38.

Pfizer Stock Performance

Pfizer stock opened at $40.10 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.22 and a quick ratio of 1.00. Pfizer Inc. has a 1-year low of $39.23 and a 1-year high of $56.32. The firm has a market capitalization of $225.33 billion, a P/E ratio of 7.32, a price-to-earnings-growth ratio of 1.33 and a beta of 0.64. The company’s 50-day moving average is $43.26 and its 200 day moving average is $46.03.

Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.11. The company had revenue of $24.30 billion for the quarter, compared to analyst estimates of $24.40 billion. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.08 EPS. Research analysts forecast that Pfizer Inc. will post 3.33 EPS for the current year.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.